Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
9-14-2020

Lurasidone and risk for metabolic syndrome: results from shortand long-term clinical studies in patients with schizophrenia
Michael Tocco
John W Newcomer
Yongcai Mao
Andrei Pikalov
Antony Loebel

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

CNS Spectrums
www.cambridge.org/cns

Original Research
Cite this article: Tocco M, Newcomer JW, Mao
Y, Pikalov A, and Loebel A (2021). Lurasidone
and risk for metabolic syndrome: results from
short- and long-term clinical studies in
patients with schizophrenia. CNS Spectrums
26(6), 614–624.
https://doi.org/10.1017/S1092852920001698
Received: 21 April 2020
Accepted: 16 July 2020
Key words
Antipsychotics; atypical; lurasidone; metabolic
syndrome; schizophrenia.
Author for correspondence:
*Michael Tocco, PhD
Email: michael.tocco@sunovion.com

Lurasidone and risk for metabolic syndrome:
results from short- and long-term clinical
studies in patients with schizophrenia
Michael Tocco1*, John W. Newcomer2,3, Yongcai Mao1, Andrei Pikalov1 and
Antony Loebel1
1

Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA, 2Thriving Mind, Miami, FL, USA, and 3Department of Psychiatry,
Washington University School of Medicine, St. Louis, MO, USA

Abstract
Objective. To assess the effects of treatment with lurasidone on risk for metabolic syndrome
(MetS) in patients with schizophrenia.
Methods. Rates of metabolic syndrome during treatment with lurasidone (40-160 mg/d) were
analyzed using pooled, short-term data from three randomized, double-blind, placebocontrolled studies (vs olanzapine and quetiapine XR); long-term data from two activecomparator-controlled studies (vs risperidone and quetiapine XR); and data from two openlabel studies in which patients were switched from olanzapine or risperidone to lurasidone.
Results. MetS was defined based on the National Cholesterol Education Program criteria. In
short-term studies, the odds of meeting criteria for MetS at week 6 LOCF (adjusted for baseline
metabolic syndrome status) was similar for the lurasidone and placebo groups (OR = 1.18; [95%
CI, 0.81-1.71]; P = .39), but the odds (vs placebo) were significantly greater for olanzapine (OR =
2.81; [95% CI, 1.53-5.15]; P < .001) and quetiapine (OR = 3.49; [95% CI, 1.93-6.29]; P < .0001).
No dose effect was observed for lurasidone across the dose range of 40-160 mg/d. In long-term
studies, the odds of MetS after 12 months of treatment was significantly higher for risperidone
compared with lurasidone (OR = 2.12; 95% CI, 1.15-3.90; P = .016) and for quetiapine XR
compared with lurasidone (OR = 3.92; 95% CI, 1.15-13.40; P = .029). In open-label extension
studies, the rate of MetS decreased in patients switched to lurasidone after 6 weeks of treatment
with olanzapine or 12 months of treatment with risperidone.
Conclusion. In this analysis of lurasidone clinical trials, the odds of developing metabolic
syndrome were minimal during short- and long-term treatment with lurasidone (40-160 mg/d).

Introduction

© The Author(s), 2020. Published by Cambridge
University Press. This is an Open Access article,
distributed under the terms of the Creative
Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.

High rates of metabolic syndrome, ranging from 29% to 35%, are observed in patients with
schizophrenia.1 The characteristic clinical and metabolic findings, comprising central obesity,
dyslipidemia, hypertension, and insulin resistance, are associated with a significant increased risk
of cardiovascular morbidity and mortality1–3 as well as cognitive impairment.4,5 In a metaanalysis of randomized clinical trials and observational studies in schizophrenia (N = 29 596
patients), the prevalence of metabolic syndrome (MetS) was 33%, representing 1.9-fold increased
odds for developing MetS compared to the general population.6 In an analysis of baseline data
from the CATIE study (N = 689 patients), significantly higher rates of metabolic syndrome were
observed (vs matched controls) for both men (36.0% vs 19.7%; P < .001) and women (51.6% vs
25.1%; P < .001).7
The extent to which the diagnosis of schizophrenia is associated with a metabolic syndrome
diathesis, independent of exposure to antipsychotic therapy, has not been fully determined. Some
evidence suggests that drug-naïve patients with schizophrenia may represent an at-risk group
with higher rates of diabetes, impaired glucose tolerance, increased insulin resistance, elevated
lipid levels, and obesity.8–14 Nonetheless, evidence is strong indicating that antipsychotic
treatment is associated with a marked increase in the rate of metabolic syndrome and its
components.1,15
While antipsychotic treatment can significantly increase the odds of developing metabolic
syndrome, there is extensive evidence of clinically and statistically significant differences in the
magnitude of risk across individual antipsychotic medications.15,16 Marked differences have
been reported in the propensity for weight gain among atypical antipsychotic medications.13–20
In meta-analyses of clinical trials in schizophrenia, mean weight gain is highest for clozapine,
olanzapine, and iloperidone; intermediate for quetiapine, risperidone, and paliperidone; and
lowest for ziprasidone, aripiprazole, lurasidone, asenapine, and amisulpride.13,17 Antipsychotics
may also have differential effects on glucose regulation and lipid metabolism that are independent of body weight.21–23
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Table 1. Summary of Studies Included in this Metabolic Syndrome Analysis.
NCT Number (Study Number)

Study Design

Study Medication, Doses (n)

Randomized, double-blind, fixed-dose, 6-week

Lurasidone, 40 mg (n = 120)

Short-Term Studies
NCT00549718 (Study 229)29

Lurasidone, 80 mg (n = 116)
Lurasidone, 120 mg (n = 123)
Placebo (n = 122)
30

Lurasidone, 40 mg (n = 119)

NCT00615433 (Study 231)

Lurasidone, 120 mg (n = 118)
Olanzapine, 15 mg (n = 122)
Placebo (n = 114)
NCT00790192 (Study 233)31

Lurasidone, 80 mg (n = 125)
Lurasidone, 160 mg (n = 121)
Quetiapine XR, 600 mg (n = 119)
Placebo (n = 121)

Longer-Term Studies
NCT00641745 (Study 237)32

Randomized, double-blind, flexible-dose, 12-month

Lurasidone, 40-120 mg (n = 415)
Risperidone, 2-6 mg (n = 199)

33

NCT00789698 (Study 234)

Randomized, double-blind, flexible-dose, 12-month; study sample
consisted of patients who completed study NCT00790192;
patients on active treatment continued on the same study
medication; patients on placebo were switched to lurasidone

Lurasidone, 40-160 mg (n = 204)

Quetiapine XR, 200-800 mg (n = 85)

Extension Studies (With Medication Switch)
NCT00641745 (Study 237-E)34

Open-label, 6-month extension of study NCT00641745 (above;
risperidone patients were switched to lurasidone)

Lurasidone ! Lurasidone, 40-120 mg (n = 136)

NCT00615433 (Study 231-E)39

Open-label, 6-month extension of study NCT00615433 (above;
olanzapine and placebo patients were switched to lurasidone)

Lurasidone ! Lurasidone, 40-120 mg (n = 115)

Several studies have implicated activity at 5-HT2C and histamine H1 receptors as a potential mechanism underlying the effects
of antipsychotics on lipids, glucose metabolism, and weight.24,25
There are notable differences among atypical antipsychotic medications in the degree of affinity for these receptors, with olanzapine
and clozapine being among the most active.24 In contrast, lurasidone exhibits weak affinity for 5-HT2C receptors and no appreciable affinity for histamine H1 or muscarinic M1 receptors.26
Lurasidone has demonstrated efficacy in short- and long-term
clinical trials in patients with schizophrenia,27–34 with limited risk
for weight gain and low rates of adverse metabolic effects.35–38 The
objective of this analysis was to assess the odds of development of
metabolic syndrome associated with lurasidone treatment of adult
patients with schizophrenia. The results summarized here include
data from double-blind, placebo-, or active-comparator-controlled
short-term (6 week) and long-term (≥12 month) trials in the lurasidone schizophrenia clinical trials database and from open-label
extension studies in the database in which patients were switched
from other atypical antipsychotic agents to lurasidone.

Methods
This analysis included data from the following clinical trials: all
three short-term placebo-controlled phase III trials that supported
FDA approval of lurasidone for the treatment of patients with

Risperidone ! Lurasidone, 40-120 mg (n = 87)

Olanzapine ! Lurasidone, 40-120 mg (n = 69)

schizophrenia; two 12-month active-comparator-controlled doubleblind studies; and the 6-month open-label extension to one of the
short-term placebo-controlled studies and the 6-month open-label
extension to one of the 12-month double-blind active-comparator
studies (see Table 1). These studies were selected since they included
data comprising all five of the NCEP ATP III criteria. The current
analysis was limited to the subgroup of patients with blood samples
obtained while fasting.
Patients were classified as having metabolic syndrome based
on the 2005 revision of the NCEP ATP III criteria40 when any
three of the following five criteria were met: elevated waist circumference (≥102 cm for men, ≥88 cm for women), elevated triglycerides (≥ 150 mg/dL), reduced high-density lipoprotein cholesterol
(<40 mg/dL in men, <50 mg/dL in women), elevated blood pressure
(systolic ≥130 mm Hg or diastolic ≥85 mm Hg), or elevated fasting
glucose (≥100 mg/dL). In the current analysis, an NCEP ATP III
criterion was not considered to be met if a patient had normal
values for triglycerides, blood pressure, high-density lipoprotein
(HDL), and/or glucose while receiving drug treatment for one or
more of these parameters.
All study protocols were approved by an independent ethics
committee or institutional review board, and written informed consent was provided by all patients before initiation of study procedures.
All studies were conducted in accordance with the International
Conference on Harmonization Good Clinical Practice guidelines
and with the ethical principles of the Declaration of Helsinki.
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Short-term studies
32–34

Patients enrolled in these three studies
were aged 18 to 75
years, had a diagnosis of schizophrenia (based on DSM-IV/ DSMIV-TR criteria), and were experiencing an acute exacerbation of
psychotic symptoms. Key exclusion criteria were an acute or unstable medical condition, alcohol or other drug abuse or dependence
within the past 6 months, evidence of a severe movement disorder,
or imminent risk of suicide (as judged by the study investigator).
Patients who met study entry criteria were randomized, doubleblinded to 6 weeks of once-daily, fixed-dose treatment with lurasidone (40, 80, 120, or 160 mg/d) or placebo (Table 1).
Long-term studies
Study D1050237 (NCT00641745) was a 12-month, randomized,
double-blind, safety study of flexibly dosed lurasidone (40-120 mg/
d) compared with risperidone (2-6 mg/d) in clinically stable outpatients with schizophrenia.32 Study D1050234 (NCT00789698)
was a 12-month, double-blind, relapse-prevention study of flexibly
dosed lurasidone (40-160 mg/d) compared with quetiapine XR
(200-800 mg/d; Table 1).33
Extension studies with medication switch
Study D1050231-E (NCT00615433) was a 6-month extension
study of open-label lurasidone that followed an initial 6-week,
randomized, double-blind study of fixed-dose lurasidone (40 or
120 mg/d), olanzapine (15 mg/d), or placebo (Study D1050231).39
The extension of Study D1050237-E (NCT00641745) was a
6-month extension study of open-label lurasidone (40-120 mg/d)
that followed an initial 12-month, randomized, double-blind study
of flexibly dosed lurasidone (40-120 mg/d) or risperidone (2-6 mg/d)
(Study D1050237; Table 1).32
Statistical methods
Short-term studies
Patient-level data were pooled for the analyses of three similarly
designed, double-blind, 6-week, phase III studies. The safety sample for each study utilized in this analysis consisted of patients who
were randomly assigned to treatment and received ≥ 1 dose of
study medication. Logistic regression analysis, adjusted for baseline
metabolic syndrome status, using a last observation carried forward
(LOCF) approach was performed to determine statistical significance for between-group differences in weight and metabolic
outcomes. Safety evaluations included vital signs, weight, waist
circumference measurements, and laboratory tests (including
lipids and glycemic indices).
To provide a preliminary assessment of the benefit of lurasidone, in terms of treatment response (≥20% reduction from baseline in PANSS total score at LOCF endpoint vs placebo), and the
risk of lurasidone treatment, in terms of clinically significant weight
gain (≥7% weight gain from baseline to endpoint vs placebo), we
calculated the likelihood to be helped or harmed (LHH) as the
NNH/NNT ratio for the two short-term trials (NCT00615433 and
NCT00790192) that included both a placebo and an active comparator drug (olanzapine and quetiapine XR).
Long-term studies
Data from two long-term, active-controlled studies of lurasidone in
the treatment of adult patients with schizophrenia were analyzed
separately due to differences in study design. Between-group

differences (D1050237: lurasidone vs risperidone; D1050234: lurasidone vs quetiapine XR) were tested for significance using logistic
regression analysis.
Extension studies with medication switch
Data from two open-label extension studies that included a medication switch to lurasidone were analyzed separately, due to differences in study design. The proportion of patients with metabolic
syndrome was calculated at extension study baseline and extension
study month 6. Patients who received continuous treatment with
lurasidone were compared with patients who switched to lurasidone from olanzapine or risperidone. Patients randomly assigned
to receive placebo in the acute phase of Study D1050231 were
excluded from this analysis.
Results
Short-term studies: pooled analyses of metabolic syndrome
A total of 1457 patients were included in the safety population, of
whom, 1203 patients had at least one postbaseline safety assessment and were included in this analysis. In the pooled short-term
studies (N = 3; D1050229, D1050231, D1050233), patients received
lurasidone (N = 852), olanzapine (N = 122), quetiapine XR (N = 119),
or placebo (N = 364) for up to 6 weeks. Of the lurasidone-treated
patients, 243 (28.5%), 246 (28.9%), 242 (28.4%), and 121 (14.2%)
patients received 40, 80, 120, and 160 mg/d, respectively. Demographic and baseline clinical characteristics are summarized
in Table 2.
The proportion of patients meeting NCEP ATP III criteria for
metabolic syndrome at baseline and week 6 (LOCF endpoint),
respectively, was 21.6% and 23.4% for lurasidone, 21.3% and
36.3% for olanzapine, 16.0% and 37.4% for quetiapine XR, and
20.7% and 20.6% for placebo (Figure 1A). The odds of meeting
NCEP ATP III criteria for metabolic syndrome at week 6 LOCF
(adjusted for baseline metabolic syndrome status) was similar for
the lurasidone and placebo groups (OR = 1.18; [95% CI, 0.81-1.71];
P = .39.), but the odds were significantly greater for olanzapine (OR
= 2.81; [95% CI, 1.53-5.15]; P < .001) and quetiapine (OR = 3.49;
[95% CI, 1.93-6.29]; P < .0001) vs placebo. The proportion of
patients with metabolic syndrome at baseline compared to week
6 (LOCF) was 26.8% vs 28.1%, respectively, for lurasidone 40 mg/d,
22.4% vs 19.7% for 80 mg/d, 19.9% vs 21.7% for 120 mg/d, and
16.1% vs 24.1% for 160 mg/d. The odds of meeting criteria for
metabolic syndrome at week 6 LOCF were similar for each dose
level of lurasidone compared to placebo, with no significant, or
trend significant, difference at any dose.
In patients who did not meet criteria for metabolic syndrome at
baseline, the proportion who met criteria for metabolic syndrome
at 6 weeks (LOCF) was significantly greater for the olanzapine
(18.6%; P < .05) and quetiapine XR (24.3%; P < .01) groups compared with both the placebo (8.4%) and lurasidone (8.4%, combined doses; Figure 1B) groups. For lurasidone doses of 40 mg/d,
80 mg/d, 120 mg/d, and 160 mg/d, the proportion who met metabolic syndrome criteria at 6 weeks (LOCF) was 7.9%, 7.2%, 8.6%,
and 11.6%, respectively (Figure 1B).
Short-term studies: analyses of individual metabolic
parameters
In the pooled short-term studies, the proportion of patients with
individual metabolic parameters that were abnormal at baseline
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Longer-Term Studies
a

Pooled [Studies 229, 231, 233]

Study 237

Studies with Medication Switch
Study 231-Eb

Study 234

Study 237-Eb

LUR

OLZ

QXR

PBO

LUR

RIS

LUR

QXR

LUR!LUR

OLZ!LUR

LUR!LUR

RIS!LUR

N = 849

N = 122

N = 119

N = 363

N = 415

N = 199

N = 207

N = 85

N = 115

N = 69

N = 136

N = 87

72.3

77.9

64.7

71.3

72.3

62.3

70.1

61.2

78.3

78.3

75

66.7

White

47.8

33.6

58

46.8

35.9

42.7

57.4

65.9

30.4

33.3

36.8

44.8

Black

30.2

36.1

16

28.7

52.8

49.7

14.2

15.3

28.7

27.5

49.3

46

Asian

19.1

24.6

21.8

19.8

3.9

1.5

25

14.1

33.9

31.9

4.4

1.1

Other

2.9

5.7

4.2

4.7

7.5

6

3.4

4.7

7

7.2

9.6

8

Characteristicc
Male, %

CNS Spectrums

Race, %

Age, y, mean

38.1

38.3

37.4

37.5

41.7

41.7

37.2

38.5

36

36.4

43.9

42.8

Duration of illness, y, mean

13.7

13.7

12.8

13.4

16.5

17.3

10.9

13.2

13.1

11.8

16.9

17.6

Weight, kg, mean

76.6

76

72.1

77.3

83.1

81.1

72.8

72.4

74.3

77.9

79.1

83.4

26.2

26

25.5

26.3

28.2

27.9

25.1

25.6

25.7

27

27

28.8

90.2

91.3

87.4

90

95.7

94.9

86.3

87.2

91.1

93.7

93.3

98.5

2

BMI, kg/m , mean
Metabolic parameters, mean
Waist circumference, cm
Abnormal (%)

29.4

31.4

21.8

28.5

41.1

46.7

22.2

21.2

27.8

37.7

35.3

55.2

HDL cholesterol, mg/dL

47.2

48.4

43.3

47.1

48

50.1

45.8

43.6

45.9

43.4

47.5

44.1

Abnormal (%)

38.4

30.3

51.3

39

34.8

35.6

44.4

54.1

37.4

44.9

39.7

58.6

Triglycerides, mg/dL

136

133.4

137.2

135

139.4

134.8

127.5

138.1

145.4

185.9

113.7

148

Abnormal (%)

29.9

29.5

28.6

29.4

35.3

30.2

28.3

30.6

34.8

47.8

18.4

34.5

120/77

121/79

120/77

120/77

122/79

121/79

120/77

120/77

117/77

121/79

122/79

124/80

Blood pressure, mm Hg
Abnormal (%)

28

34.4

26.1

26.6

37.5

41.1

21.3

24.7

25.2

36.2

41.9

47.1

Glucose, mg/dL

95.1

94.1

93.2

95

95.7

95.4

93.2

92.8

94.8

102

98.9

98.4

Abnormal (%)

27.2

25.4

18.5

26.9

31.6

27.2

22.5

17.6

30.4

29

33.1

40.2

Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LUR, lurasidone; OLZ, olanzapine; PBO, placebo; QXR, quetiapine; RIS, risperidone.
a
Pooled for patients with metabolic syndrome data at baseline and ≥ 1 postbaseline assessment.29–31
For the two switch studies,34, 39 data shown are for the open-label baseline following double-blind treatment, at the switch (or continuation) time-point.
c
Sample sizes vary based on data availability.
d
Abnormal criteria: elevated waist circumference (≥102 cm for men, ≥88 cm for women), elevated triglycerides (≥150 mg/dL), reduced HDL (<40 mg/dL in men, <50 mg/dL in women), elevated BP (systolic ≥130 mm Hg or diastolic ≥85 mm Hg), or elevated
fasting glucose (≥100 mg/dL).

b
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Metabolic Syndrome, %

50%

40%

*** P<0.001 (vs. placebo)
Baseline

Week 6 (LOCF)

***

***

37.4%

36.3%

30%

21.6%

23.4%

21.3%

20.7% 20.6%

20%

16.0%

10%

0%

Lurasidone
(N=852)

Queapine XR
(N=119)

Olanzapine
(N=122)

Placebo
(N=364)

50%

Paents with Endpoint Shi to
Metabolic Syndrome, %

* P<0.05 (vs. combined lurasidone doses and placebo)
** P<0.01 (vs. combined lurasidone doses and placebo)
40%

30%

**
24.3%

*
18.6%

20%

11.6%
10%

7.9%

7.2%

40 mg
(n=243)

80 mg
(n=246)

8.6%

8.4%

0%
120 mgWeek
160
mg Olanzapine Queapine
6 (LOCF)
(n=122)
(n=119)
(n=242)
(n=121)

Placebo
(n=364)

Lurasidone
Figure 1. Metabolic syndrome status: pooled short-term studies.18–20 (A) Proportion of patients meeting metabolic syndrome criteria at baseline and week 6 (LOCF). (B) Proportion
of patients without metabolic syndrome at baseline who met criteria for metabolic syndrome at week 6 (LOCF).
Abbreviation: LOCF, last observation carried forward.

(based on NCEP ATP III criteria; all treatment groups combined)
was 28.7% for waist circumference, 29.6% for triglycerides, 38.9%
for HDL, 28.0% for blood pressure, and 26.3% for glucose (Table 2).
Mean increase in weight and waist circumference and median
increase in triglyceride and glucose levels from baseline to
6-week endpoint were greater in patients treated with olanzapine
or quetiapine XR compared with patients who received placebo
(Table 2). The largest increases at 6 weeks were associated with
olanzapine treatment, most notably in weight (+4.2 kg), waist
circumference (+3.4 cm), and triglycerides (+25.5 mg/dL). Changes
in metabolic parameters at week 6 (LOCF endpoint) on lurasidone
were similar to placebo, with the exception of a modest mean
increase in waist circumference (+0.9 cm vs +0.3 cm).

Short-term studies: benefit–risk for treatment response
Two placebo-controlled, short-term trials included an active comparator. In the first trial (NCT00615433) that included olanzapine
as an active comparator, the NNH for weight gain (≥ 7%) was
100 for lurasidone and 4 for olanzapine. The NNT for treatment

response was 9 for lurasidone and 4 for olanzapine. The resulting
likelihood of being helped or harmed (LHH) for lurasidone was
11.1 vs 1 for olanzapine (higher LHH values indicate a more
favorable benefit–risk ratio for a medication). In the second trial
(NCT00790192) which included quetiapine XR as an active comparator, the NNH for weight gain was 56 for lurasidone and 8 for
quetiapine XR. The NNT for treatment response was 4 for lurasidone and 3 for quetiapine XR. The resulting benefit–risk LHH for
lurasidone was 14 compared to 2.7 for quetiapine XR.

Individual analyses of long-term studies: metabolic syndrome
The safety population of Study D1050237 included 621 patients
(Table 2), of whom 147 lurasidone-treated and 90 risperidonetreated patients had metabolic syndrome data at baseline and at
month 12. The safety population of study D1050234 included
292 patients (Table 2), of whom 102 lurasidone-treated and 85 quetiapine XR–treated patients had metabolic syndrome data at the
initial study baseline and at month 12 of the relapse prevention
study.
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Randomized, double-blind, ﬂexible-dose,
12-month Maintenance Trial

Randomized, double-blind, ﬂexible-dose,
12-month Relapse Prevenon Trial

D1050237

D1050234

Baseline

50%

Month 12

*
41.3%

*P<0.05 vs. lurasidone (week 12)

Baseline

30%

Month 12

*P<0.05 vs. lurasidone (week 12)
*

30.1%
30%

Metabolic Syndrome, %

Metabolic Syndrome, %

40%

28.6%

26.8%

20%

21.2%
20%
16.7%
15.3%
10.6%
10%

10%

0%

415

149

199

Lurasidone

92

0%

Risperidone

204

104

Lurasidone

Queapine XR

D1050234

D1050237

* P<0.05 vs. lurasidone

30%

*
20.0%
20%

11.6%
10%

0%

Paents Shiing to Metabolic Syndrome, %

Paents Shiing to Metabolic Syndrome, %

33

Randomized, double-blind, ﬂexible-dose,
12-month Relapse Prevenon Trial

Randomized, double-blind, ﬂexible-dose,
12-month Maintenance Trial
30%

85

* P<0.05 vs. lurasidone

20%

*
15.2%

10%

3.9%

0%

Lurasidone (N=147)

Risperidone (N=90)

Lurasidone (N=102)

Queapine XR (N=85)

Figure 2. Metabolic syndrome status: long-term studies. (A) Proportion of patients meeting metabolic syndrome criteria at baseline and month 12 in two long-term studies (observed
cases). (B) Proportion of patients without metabolic syndrome at baseline who met criteria for metabolic syndrome at month 12 in two long-term studies (observed cases).

In Study D1050237, the percentage of patients who met NCEP
ATP III criteria for metabolic syndrome at baseline and month
12, respectively, was 30.1% and 26.8% in the lurasidone group and
28.6% and 41.3% in the risperidone group (Figure 2A; left panel).
The odds of metabolic syndrome after 12 months of treatment was
significantly higher for risperidone compared with lurasidone (OR
= 2.12; 95% CI, 1.15-3.90; P = .016). In patients who did not meet
criteria for metabolic syndrome at baseline, the proportion who
met criteria for metabolic syndrome after 12 months of treatment
was significantly lower for lurasidone vs risperidone (11.6% vs
20.0% [OC]; P < .05; Figure 2B; left panel).
In Study D1050234, the percentage of patients who met NCEP
ATP III criteria for metabolic syndrome at baseline and month
12, respectively, was 16.7% and 10.6% in the lurasidone group and
15.3% and 21.2% in the quetiapine XR group (Figure 2A; right
panel). The odds of metabolic syndrome after 12 months of treatment was significantly higher for quetiapine XR compared with
lurasidone (OR = 3.92; 95% CI, 1.15-13.40; P = .029). In patients who

did not meet criteria for metabolic syndrome at baseline, the proportion who met criteria for metabolic syndrome after 12 months of
treatment was significantly lower for lurasidone vs quetiapine XR
(3.9% vs 15.2% [OC]; P < .05; Figure 2B; right panel).
Analyses of long-term studies: individual metabolic parameters
In Study D1050237, the proportion of patients with individual
metabolic parameters that were abnormal at baseline (based on
NCEP ATP III criteria; all treatment groups combined) was 42.9%
for waist circumference, 33.7% for triglycerides, 35.1% for HDL,
38.6% for blood pressure, and 30.1% for glucose (Table 2). In Study
D1050237, 12 months of treatment with lurasidone was associated
with reduction in weight (1.0 kg), waist circumference (0.4 cm),
and triglycerides (8.5 mg/dL), whereas treatment with risperidone was associated with increases in weight (+2.6 kg), waist
circumference (+2.6 cm), and glucose (+4.0 mg/dL) and a decrease
in HDL cholesterol (4.0 mg/dL; Table 3).
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Table 3. Change from Baseline in Weight and Metabolic Parameters.
Short-Term Studies

Longer-Term Studies

Studies with Medication Switch

Pooled (Studies 229, 231, 233)

Study 237

Study 234

Study 231-E

Study 237-E

Week 6 (LOCF)

Month 12 (OC)

Month 12 (OC)a

Month 6 (OC)b

Month 6 (LOCF)b

LUR

OLZ

QXR

PBO

LUR

RIS

LUR

QXR

LUR-LUR

OLZ-LUR

LUR-LUR

RIS-LUR

N = 849

N = 122

N = 119

N = 363

N = 415

N = 199

N = 207

N = 85

N = 56

N = 31

N = 109

N = 66

Weight, kg

+0.9

+4.2

+2.1

+0.3

1.0

+2.6

+0.8

+1.2

+0.4

1.9

0.6

2.9

Waist circumference,
cm

+1.1

+3.4

+1.8

+0.3

0.4

+2.6

+1.1

+0.6

0.0

2.8

1.0

1.7

HDL cholesterol,
mg/dL

0.0

2.0

0.0

2.0

0.0

4.0

0.0

+4.0

2.0

2.0

0.0

+4.0

Measurec,d

Triglycerides, mg/dL

3.0

+25.5

+11

6.0

8.5

0.0

18.0

7.0

5.0

28.0

4.5

5.5

Systolic blood
pressure, mm Hg

0.0

+1.6

+1.4

+0.7

+1.0

+1.3

+0.4

+3.3

+2.1

+3.3

+2.8

+0.9

Diastolic blood
pressure, mm Hg

+0.5

+1.2

+1.7

+0.5

0.1

0.7

+0.5

+1.2

+0.9

+1.7

+0.8

+0.3

Glucose, mg/dL

0.0

+4.0

+4.0

+1.0

0.0

+4.0

0.0

+1.0

+3.0

0.0

0.0

3.0

Abbreviations: HDL, high-density lipoprotein; LOCF, last observation carried forward; LUR, lurasidone; OC, observed cases; OLZ, olanzapine; PBO, placebo; QXR, quetiapine; RIS, risperidone.
a
Change from baseline of the preceding 6-week, double-blind study.
b
Change from extension study baseline to month 6.
c
Mean change is reported for weight, waist circumference, and blood pressure; median change is reported for HDL, triglycerides, and glucose.
d
Sample sizes vary based on data availability.

In Study D1050234, the proportion of patients with individual
metabolic parameters that were abnormal at baseline (based on
NCEP ATP III criteria; all treatment groups combined) was 21.9%
for waist circumference, 29.0% for triglycerides, 47.2% for HDL,
22.3% for blood pressure, and 21.1% for glucose (Table 2). In Study
D1050234, 12 months of treatment with lurasidone was associated
with a small increase in weight (+0.8 kg) and waist circumference
(+1.1 cm) and a reduction in triglycerides (18.0 mg/dL), whereas
treatment with quetiapine XR was associated with increased weight
(+1.2 kg) and minimal increase in waist circumference (+0.6 cm;
Table 3).
Extension studies with medication switch: individual study
analyses
In patients with available metabolic data who completed 6 weeks
of treatment with lurasidone (N = 115) or olanzapine (N = 69)
and who entered the 6-month extension study (D1050231-E),
the percentage of patients who met NCEP ATP III criteria for
metabolic syndrome at open-label (switch) baseline and month
6 (LOCF), respectively, was 25.2% and 22.9% in patients who
continued on lurasidone and 29.0% and 21.8% in patients who
switched from olanzapine to lurasidone (Figure 3A). Body weight,
waist circumference, and triglyceride level increased during 6
weeks of treatment with olanzapine; while reduction in each of
these parameters was observed after switching to 6 months of openlabel treatment with lurasidone (Table 3).
In patients with available metabolic data (87.4% of the safety
population) who completed 12 months of treatment with lurasidone (N = 136) or risperidone (N = 87) and who entered the
6-month extension study (D1050237-E), the percentage of patients
who met NCEP ATP III criteria for metabolic syndrome at openlabel (switch) baseline and month 6 (LOCF), respectively, was
25.7% and 24.6% in patients who continued on lurasidone and
42.5% and 32.9% in patients who switched from risperidone to
lurasidone (Figure 3B). Body weight and waist circumference

increased during 12 months of treatment with risperidone; while
reduction in each of these parameters was observed after switching
to 6 months of open-label treatment with lurasidone (Table 3).
Discussion
This pooled analysis of short- and long-term studies from the
lurasidone schizophrenia clinical trial database, which included
active comparators, demonstrated that the odds of developing
metabolic syndrome, based on NCEP ATP III criteria, were low
during treatment with lurasidone. In contrast, the odds (vs placebo)
of developing metabolic syndrome were significantly higher for
olanzapine and quetiapine XR in two short-term trials and for
quetiapine XR and risperidone (vs lurasidone) during long-term
trials.
The proportion of patients with schizophrenia meeting NCEP
ATP III criteria for metabolic syndrome remained unchanged
during 6 weeks of treatment with lurasidone and placebo. Notably,
no dose effect on the prevalence rate of metabolic syndrome was
observed during 6 weeks of treatment with lurasidone, across the
dose range of 40 to 160 mg/d. In contrast, the proportion of patients
meeting criteria for metabolic syndrome was significantly
increased from baseline to week 6 by 15% and 21.4%, respectively,
in patients treated with olanzapine or quetiapine XR.
In patients who did not meet NCEP ATP III criteria for metabolic syndrome at pretreatment baseline, the proportion who met
criteria after 6 weeks of treatment was similar for lurasidone and
placebo (8.4% for both treatment groups). In contrast, the proportion of patients meeting full criteria for metabolic syndrome after 6
weeks of treatment was significantly higher (vs placebo) for olanzapine (18.6%) and quetiapine XR (24.3%).
In the current short-term trials, the proportion of patients
meeting NCEP ATP III criteria for metabolic syndrome at baseline
(prior to randomization) was approximately 20%. This is lower
than the overall prevalence rate of 32.5% reported in a large metaanalysis of patients with a diagnosis of schizophrenia.1 Baseline
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DB Baseline

OL Baseline
(aer 6 weeks of DB treatment)

6-Month Switch Endpoint
(LOCF)

Paents meeng criteria for
metabolic syndrome, %

50%

40%

29.0%

30%

25.2%
20.9%

22.9%

21.7%

21.8%

20%

10%

0%

Lurasidone (N=115)

Olanzapine (N=69)

LUR

LUR

OLZ

LUR

OL: open-label; DB: double-blind; LUR: lurasidone; OLZ: olanzapine

DB Baseline

OL Baseline
(aer 12 months of DB treatment)

6-Month Switch Endpoint
(LOCF)

50%

Paents meeng criteria for
metabolic syndrome, %

42.5%
40%

30%

29.1%

32.9%

30.6%
25.7%

24.6%

20%

10%

0%

Lurasidone (N=136)

Risperidone (N=87)

LUR

LUR

RIS

LUR

OL: open-label; DB: double-blind; LUR: lurasidone; RIS: risperidone
Figure 3. Metabolic syndrome status at month 6 (LOCF endpoint) in two medication switch studies. (A) Proportion of patients meeting metabolic syndrome criteria before and
after 6 weeks of double-blind treatment with lurasidone vs olanzapine and after 6 months of open-label treatment with lurasidone (olanzapine patients were switched to
lurasidone). (B) Proportion of patients meeting metabolic syndrome criteria before and after 12 months of double-blind treatment with lurasidone vs risperidone and after 6
months of open-label treatment with lurasidone (risperidone patients were switched to lurasidone). Abbreviations: LOCF, last observation carried forward; LUR, lurasidone; OLZ,
olanzapine; RIS, risperidone.

prevalence of abnormal individual metabolic parameters was also
lower in the current study vs results reported in the Mitchell et al
meta-analysis,1 for example, 28.7% vs 49.4% for abnormal waist
circumference. The reason for the lower prevalence rate of metabolic syndrome at baseline in the current analyses, and lower
baseline rates of abnormal individual metabolic parameters, may
be due to use of standard phase III entry criteria that excluded most
medical comorbidities.
Results from our analysis of two long-term, double-blind,
active-comparator studies in patients with schizophrenia further
support the minimal metabolic effect of lurasidone relative to
risperidone and quetiapine XR. The odds of having metabolic

syndrome after 12 months of treatment were significantly greater
for patients treated with risperidone or quetiapine XR compared to
patients treated with lurasidone.
Prospective results from two open-label extension studies
thatincluded a medication switch also suggest that worsening
metabolic parameters during initial treatment with olanzapine
(6 weeks) or risperidone (12 months) can partially be reversed by
switching patients to lurasidone (for 6 months). Prevalence rates
for metabolic syndrome decreased by 7.2% in patients who
switched from olanzapine to lurasidone and by 9.6% in patients
who switched from risperidone to lurasidone. Similar improvement in metabolic parameters, and/or rates of metabolic
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syndrome, have also been reported after switch to aripiprazole
and ziprasidone.41–44
The increase in rate of metabolic syndrome observed after
short-term treatment with olanzapine and quetiapine XR, and after
long-term treatment with risperidone and quetiapine XR in the
lurasidone schizophrenia database, is consistent with the known
propensity of these agents to produce weight gain and metabolic
disturbance.15,45–47
The low risk of metabolic syndrome observed here for lurasidone may be related to its receptor-binding profile which exhibits
no clinically relevant affinity for receptors such as histamine H1
(Ki, > 1000) and 5-HT2C (Ki, 415)26 that are known to be associated
with weight gain.24,25 In a preclinical study, lurasidone has also
been shown to have no effect on insulin resistance.48 In contrast,
atypical antipsychotics associated with higher risk of weight gain
and metabolic syndrome (eg, olanzapine, quetiapine, and risperidone) have notably higher affinity for histamine H1 and 5-HT2C
receptors and have been shown to be associated with glucose
intolerance and increased insulin resistance.24,48–50 Preliminary
preclinical data in rodents also suggest that lurasidone, when
coadministered with olanzapine, may suppress food intake and
weight gain associated with olanzapine.51
The diagnosis of schizophrenia is associated with significantly
increased cardiovascular morbidity, excess mortality, and an
approximately 20-year shorter life span when compared to nonschizophrenia cohorts.52 Metabolic syndrome significantly contributes to this excess morbidity and mortality risk.52 The results
of this pooled analysis provide further support for treatment guideline recommendations that clinicians should routinely monitor
body weight and metabolic parameters throughout the course of
treatment with antipsychotic agents.
Early behavioral interventions (eg, exercise, change in diet) are
typically recommended if clinically significant weight gain or metabolic abnormalities develop during treatment with atypical antipsychotics.50 However, the ability of such interventions to yield
sustained improvement in weight or metabolic parameters in the
face of continued antipsychotic therapy has not been established.53
Based on current data, it appears that switching to a metabolically
safe medication provides greater improvement than exercise
or diet.53
The current analyses were not designed to provide a systematic
benefit–risk comparison of lurasidone to other antipsychotics and
were limited to the active comparator medications included in the
available trials. However, LHH is a widely used benefit–risk parameter that allowed us to obtain a preliminary composite index of
efficacy relative to metabolic safety for lurasidone, olanzapine, and
quetiapine XR during short-term treatment. We utilized weight
gain as the safety parameter since it is highly correlated with
adverse metabolic effects and is frequently used as a proxy for
metabolic outcomes.47 Consistent with results from a previous
meta-analysis,54 olanzapine had a notably higher short-term response
rate compared to lurasidone and quetiapine XR. However, the markedly higher rate of weight gain associated with olanzapine treatment,
even during a 6-week trial, resulted in an unfavorable benefit–risk
profile for this medication. Patients treated with olanzapine were
equally likely to benefit from treatment as they were to be harmed
by significant weight gain (LHH = 1), whereas, lurasidone-treated
patients were 11 times more likely to benefit from treatment than be
harmed by significant weight gain (LHH = 11.1). In the second
short-term study, lurasidone-treated patients were 14 times more
likely to benefit than be harmed (LHH = 14), while patients

receiving quetiapine XR were over twice as likely to experience
benefit than harm (LHH = 2.7).
Limitations of the current analysis include, first, the possible
bias introduced by study attrition, particularly during long-term
treatment studies, resulting in reduced exposure that might lead to
an underestimation of the effect of treatment on weight and
metabolic parameters. Second, sample sizes were smaller in the
active comparator groups thus making estimates of metabolic
effects less robust for these medications. Third, it is possible that
some patients in the current trials were nonfasting which also may
have introduced bias in our estimates of medication treatment
effects. Fourth, the current results are limited to studies in the
lurasidone schizophrenia clinical trials database for which data
comprising of all five individual NCEP ATP III criteria were
available. And finally, it should be noted that the comparator
antipsychotics in the current analyses (olanzapine, risperidone,
quetiapine) have previously demonstrated clinically significant
adverse weight and metabolic effects; therefore, the current results
for lurasidone may not be generalizable to other typical and atypical antipsychotic drugs (eg, haloperidol and aripiprazole) that have
been shown to have minimal adverse weight and metabolic effects.
It should be noted, however, that the results of a meta-analysis of
>18 000 patients with schizophrenia treated with antipsychotics
in controlled trials52 found lurasidone to have a low relative risk
(vs placebo, RR = 1.23) for clinically significant weight gain (≥7%)
compared to the relative risk associated with aripiprazole (RR =
1.86) and haloperidol (RR = 2.02). Consistent with the current results,
the relative risk for clinically significant weight gain was markedly
higher for risperidone (RR = 3.64), quetiapine (RR = 4.50), and olanzapine (RR = 5.61).54
Conclusions
The results of this analysis of short-term and long-term trials from
the lurasidone clinical trials database found that treatment with
lurasidone, in the dose range of 40 to 160 mg/d, was associated with
a low risk for the development of metabolic syndrome in patients
with schizophrenia. These findings contrast with the incidence of
metabolic syndrome observed in patients receiving short- and longterm treatment with olanzapine, quetiapine XR, and risperidone.
Given that patients with schizophrenia are at significantly
increased risk for cardiovascular disease, type II diabetes, and
early death, the favorable metabolic profile of lurasidone, taken
together with its demonstrated efficacy in short- and long-term
trials,27–34 makes it an important treatment option for patients
with schizophrenia.
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